Biodexa Pharmaceuticals Plc
BDRXHealthcare|Biotechnology|GB
$2.48
+0.07 (+2.88%)
DCF Value
$0.42
Tangible Book / Share
$0.19
Cash / Share
$0.17
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06950385 Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis | Familial Adenomatous Polyposis (FAP) | P3 | Recruiting | 168 | RCT, Double-blind | eRapa (encapsulated rapamycin), Placebo |
| NCT04230499 Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance | Familial Adenomatous Polyposis | P2 | Completed | 30 | Open-label | Encapsulated Rapamycin (eRapa) |
| NCT05324501 A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma | Recurrent Glioblastoma | P1 | Terminated | 4 | Open-label | MTX110 |
| NCT07689942 Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis | Familial Adenomatous Polyposis (FAP) | AVAILABLE | — | — | eRapa (encapsulated rapamycin) |